Cerus Corporation
1.74
0.07 (4.19%)
At close: Jan 14, 2025, 3:59 PM
1.69
-2.87%
After-hours Jan 14, 2025, 07:04 PM EST
undefined%
Bid 1.64
Market Cap 323.14M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.11
PE Ratio (ttm) -15.82
Forward PE n/a
Analyst Buy
Ask 1.75
Volume 1,700,810
Avg. Volume (20D) 1,580,596
Open 1.71
Previous Close 1.67
Day's Range 1.69 - 1.78
52-Week Range 1.38 - 2.59
Beta undefined

About CERS

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed t...

Sector Healthcare
IPO Date Jan 31, 1997
Employees 625
Stock Exchange NASDAQ
Ticker Symbol CERS

Analyst Forecast

According to 3 analyst ratings, the average rating for CERS stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 72.41% from the latest price.

Buy 66.67%
Hold 33.33%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Cerus Corporation is scheduled to release its earnings on Mar 4, 2025, during market hours.
Analysts project revenue of $50.69M, reflecting a 8.39% YoY growth and earnings per share of -0.01, making a 0.00% YoY.
2 months ago · Source
-8.72%
Cerus shares are trading lower after the company r... Unlock content with Pro Subscription
2 months ago · Source
-9.44%
Cerus shares are trading lower after Stifel cut its price target on the stock from $6 to $3.